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Abstract: Primary pleomorphic adenomas (PAs) and mucoepidermoid carcinomas (MECs) of the breast
are vanishingly rare. Here we sought to determine whether breast PAs and MECs would be underpinned
by the fusion genes reported to occur in their salivary gland counterparts. Our study included three
breast PAs and one breast MEC, which were subjected to RNA sequencing (PAs, n = 2; MEC, n = 1) or
to Archer FusionPlex sequencing (PA, n = 1). Our analyses revealed the presence of the HMGA2-WIF1
fusion gene in breast PA3, the CTNNB1-PLAG1 fusion gene in breast PA2, and the CRTC1-MAML2
fusion gene in the breast MEC analyzed (1/1). No oncogenic fusion genes were detected in breast PA1,
and no additional oncogenic fusion genes were detected in the cases studied. The presence of the fusion
genes identified was validated by fluorescence in situ hybridization (n = 1), reverse transcription-PCR (n
= 1), or by both methods (n = 1). Taken together, our findings indicate that PAs and MECs arising in
the breast resemble their salivary gland counterparts not only phenotypically but also at the genetic level.
Furthermore, our data suggest that the molecular analysis of breast PAs and MECs might constitute a
useful tool to aid in their differential diagnosis.
DOI: https://doi.org/10.1038/s41523-020-0164-0






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Pareja, Fresia; Da Cruz Paula, Arnaud; Gularte-Mérida, Rodrigo; Vahdatinia, Mahsa; Li, Anqi; Geyer,
Felipe C; da Silva, Edaise M; Nanjangud, Gouri; Wen, Hannah Y; Varga, Zsuzsanna; Brogi, Edi; Rakha,
Emad A; Weigelt, Britta; Reis-Filho, Jorge S (2020). Pleomorphic adenomas and mucoepidermoid carci-
nomas of the breast are underpinned by fusion genes. NPJ Breast Cancer, 6:20.
DOI: https://doi.org/10.1038/s41523-020-0164-0
ARTICLE OPEN
Pleomorphic adenomas and mucoepidermoid carcinomas
of the breast are underpinned by fusion genes
Fresia Pareja 1,6✉, Arnaud Da Cruz Paula2,6, Rodrigo Gularte-Mérida 1,2,6, Mahsa Vahdatinia1, Anqi Li 1, Felipe C. Geyer1,
Edaise M. da Silva 1, Gouri Nanjangud3, Hannah Y. Wen1, Zsuzsanna Varga 4, Edi Brogi1, Emad A. Rakha5, Britta Weigelt1 and
Jorge S. Reis-Filho 1✉
Primary pleomorphic adenomas (PAs) and mucoepidermoid carcinomas (MECs) of the breast are vanishingly rare. Here we sought
to determine whether breast PAs and MECs would be underpinned by the fusion genes reported to occur in their salivary gland
counterparts. Our study included three breast PAs and one breast MEC, which were subjected to RNA sequencing (PAs, n= 2; MEC,
n= 1) or to Archer FusionPlex sequencing (PA, n= 1). Our analyses revealed the presence of the HMGA2-WIF1 fusion gene in breast
PA3, the CTNNB1-PLAG1 fusion gene in breast PA2, and the CRTC1-MAML2 fusion gene in the breast MEC analyzed (1/1). No
oncogenic fusion genes were detected in breast PA1, and no additional oncogenic fusion genes were detected in the cases studied.
The presence of the fusion genes identified was validated by fluorescence in situ hybridization (n= 1), reverse transcription-PCR
(n= 1), or by both methods (n= 1). Taken together, our findings indicate that PAs and MECs arising in the breast resemble their
salivary gland counterparts not only phenotypically but also at the genetic level. Furthermore, our data suggest that the molecular
analysis of breast PAs and MECs might constitute a useful tool to aid in their differential diagnosis.
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INTRODUCTION
Pleomorphic adenomas (PAs) and mucoepidermoid carcinomas
(MECs) of the breast are rare tumors that histologically resemble
their salivary gland counterparts1. PAs are characterized by an
admixture of epithelial and myoepithelial cells immersed in
myxochondroid stroma1,2. Cartilaginous and osseous metaplasia
may be present1,2. Breast PAs usually have a benign course,
although local recurrences have been described1. PAs arising in
the salivary glands, skin, and soft tissue harbor recurrent gene
rearrangements involving PLAG1 or HMGA2 (refs. 3,4). MECs,
although common in the salivary glands, are vanishingly rare in
the breast1,5. MECs are characterized by the admixture of
different cell types, including mucinous, intermediate, and
squamous cells1. MECs arising in the salivary gland, lung, and
cervix have been shown to harbor the t(11,19)(q14–21; p12–13)
translocation that results in the CRTC1-MAML2 fusion gene6–8, or
less frequently the CRTC3-MAML2 fusion gene9.
A subset of salivary gland-like tumors arising in the breast
have been shown to be underpinned by the same genetic
alterations as their salivary glands counterparts1,10. For instance,
adenoid cystic carcinomas arising either in the breast or in the
salivary glands harbor MYB or MYBL1 rearrangements, regardless
of their anatomic origin10–12, and secretory carcinomas of the
breast and mammary analog secretory carcinomas of the
salivary glands are characterized by the ETV6-NTRK3 fusion
gene10,13,14. The genetic underpinning of other breast salivary
gland-like tumors, such as acinic cell carcinomas, however, is
different than that of their salivary gland counterparts. Salivary
gland acinic cell carcinomas are characterized by the t(4;9)(q13;
q31) translocation, which results in a rearrangement involving
the nuclear transcription factor NR4A3 (ref. 15), whereas breast
acinic cell carcinomas seem not to harbor a pathognomonic
genetic alteration and consistently display complex genomes
and TP53 mutations16,17. Here we sought to determine whether
breast PAs and MECs arising in the breast would be underpinned




Three PAs and one MEC arising in the breast were included in this
study. The breast PAs (n= 3) included in our series were well-
circumscribed lesions (Fig. 1a), composed of epithelial cells and
myoepithelial cells arranged in cords, clusters, and forming glands
immersed in a myxochondroid stroma (Fig. 1b, c). Myoepithelial
cells floating in the stroma as single stellate cells (Fig. 1b) and focal
areas of solid growth were frequently observed (Fig. 1d). No
cellular atypia or increased mitotic index were detected (Fig. 1d)
The breast MEC studied here corresponded to a low-grade MEC
with well-circumscribed borders (Fig. 1e), composed of mucinous,
intermediate, and squamous cells arranged in cords, sheets, and
clusters (Fig. 1e). No cytologic atypia or necrosis were observed
(Fig. 1e, f).
To determine whether the breast PAs (n= 3) and the MEC
(n= 1) included in our series would harbor fusion genes, akin to
their counterparts arising in the salivary glands, we subjected
two breast PAs (BPA1 and BPA3) and one MEC (BMEC2) to RNA
sequencing (Fig. 1g, Supplementary Table 1). RNA-sequencing
data were analyzed using a validated bioinformatics pipeline for
de novo discovery of fusion genes as previously described18,19.
RNA derived from one breast PA (BPA2) with insufficient
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Fig. 1 Histologic features of and fusion genes in breast pleomorphic adenomas and a mucoepidermoid carcinoma. a–d Representative
photomicrographs of hematoxylin and eosin (H&E)-stained sections of breast pleomorphic adenomas (PAs) included in this study. Breast PAs
were well-circumscribed lesions (a), composed of epithelial and myoepithelial cells in a myxochondroid stroma (b, c). Focal areas with solid
growth were also identified (d). e, f Representative photomicrographs of H&E-stained sections of the breast mucoepidermoid carcinoma
(MEC) displaying squamous, mucinous, and intermediate cells (e), and absence of atypia or necrosis (f). g Heatmap depicting fusion genes
identified in breast pleomorphic adenomas (BPAs; n=3) and a breast mucoepidermoid carcinoma (BMEC2; n=1). Cases are shown in columns
and fusion genes in rows. Tumor type and detection method are shown (top). Scale bars, 200μm (a), 100μm (b, e), 50μm (c, d), and 20μm (f).
FISH fluorescence in situ hybridization.
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material for RNA sequencing was subjected to Archer FusionPlex
analysis, a targeted RNA-based assay, for fusion gene detection
(Fig. 1g, Supplementary Table 1). Our analyses revealed
the presence of fusion genes in two of the three breast
PAs and in the breast MEC analyzed (Fig. 1g, Supplementary
Table 1).
HMGA2 and PLAG1 rearrangements in breast pleomorphic
adenomas
Our analyses revealed the presence of an HMGA2-WIF1 fusion
gene in BPA3 by RNA sequencing (Figs. 1g and 2a, Supplementary
Table 1). The HMGA2-WIF1 fusion gene identified has been
previously reported in PAs of the salivary gland20,21. HMGA2
Fig. 2 Fusion genes identified in breast pleomorphic adenomas. a Schematic representation of the HMGA2-WIF1 fusion transcript detected
in the pleomorphic adenoma BPA3 by RNA sequencing, depicting the exons and protein domains involved (top). Vertical lines show the
breakpoints of HMGA2 andWIF1. The spanning reads found to cross the genomic breakpoint of the HMGA2-WIF1 chimeric transcript are shown
aligned to the predicted junction sequence (bottom). b Representative Sanger sequencing electropherogram of cDNA validating the HMGA2-
WIF1 fusion junction in BPA3. c Schematic representation showing the reads per kilobase per million (RPKM) mapped read counts of each
HMGA2 exon in the pleomorphic adenoma BPA3. The HMGA2 fusion breakpoint is represented as a red dashed line. d Schematic
representation of the CTNNB1-PLAG1 fusion transcript identified in the pleomorphic adenoma BPA2 by Archer FusionPlex, depicting the exons
and protein domains involved. Vertical lines show the breakpoints of CTNNB1 and PLAG1. e Representative photomicrographs of a
hematoxylin and eosin-stained section (left) and fluorescence in situ hybridization using PLAG1 dual-color break-apart probes (red, 5′ PLAG1,
green, 3′ PLAG1; right) of BPA2. Scale bar, 20 μm (e). AcD acidic domain, DBD DNA-binding domain, SpD spacer domain, Arm Armadillo repeat,
zf-H2C2 Zinc finger double domain, zf-C2H2 Zinc finger C2H2 type.
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encodes for a transcriptional regulator of the TGF-β signaling
pathway22, and WIF1 for a tumor suppressor modulating signaling
via the Wnt pathway20. The HMGA2-WIF1 fusion gene detected in
BPA3 resulted in a chimeric transcript composed of exons 1–3 of
HMGA2 and exon 10 ofWIF1, and was predicted to be translated in
the initial segment of HMGA2 fused to the C′-terminus of WIF1,
with the loss of its active WIF domain20 (Fig. 2a). The HMGA2-WIF1
fusion gene identified in BPA3 was validated by reverse
transcription (RT)-PCR, followed by Sanger sequencing (Fig. 2b).
As predicted, the HMGA2-WIF1 fusion resulted in retained
expression of HMGA2 exons 1–3 and decreased expression of
exons 4 and 5 (Fig. 2c). We identified the presence of a CTNNB1-
PLAG1 fusion gene in BPA2 by Archer FusionPlex targeted RNA
sequencing (Figs. 1g and 2d, Supplementary Table 1). The
CTNNB1-PLAG1 fusion gene was predicted to result in a chimeric
transcript encompassing exon 1 of CTNNB1 and exons 4 and 5 of
PLAG1 (Fig. 2d) and has been described in PAs of the salivary
glands and of the lacrimal glands23,24. The CTNNB1-PLAG1 fusion
identified in BPA2 was validated by fluorescence in situ hybridiza-
tion (FISH) using PLAG1 dual-color break-apart probes (Fig. 2e).
No additional likely pathogenic fusion genes were identified in the
breast PAs analyzed (Supplementary Tables 1 and 2).
Given that HMGA2 and PLAG1 rearrangements are the hallmark
genetic alterations of PAs, regardless of their anatomic location3,4,
we subjected the breast PA included in this study in which no
fusion genes were identified by RNA sequencing (BPA1) to FISH
analysis using HMGA2 and PLAG1 dual-color break-apart probes,
which confirmed the absence of HMGA2 or PLAG1 rearrangements
(Supplementary Table 1). Notably, BPA1 did not differ histologi-
cally from the PAs found to harbor fusion genes.
Breast adenomyoepitheliomas and PAs may show histologic
and genetic overlap25. Indeed, we have reported on a bona fide
breast adenomyoepithelioma displaying focal myxoid matrix and
harboring an HMGA2-WIF1 fusion gene26. Hence, we sought to
determine whether the breast PAs of this series subjected to RNA
sequencing would harbor hotspot mutations27 affecting HRAS,
PIK3CA, and AKT1 as in breast adenomyoepitheliomas28. Upon
manual inspection of the HRAS Q61 hotspot locus, PIK3CA H1047,
E545, E542, G118, G1050, and G106 hotspot loci and AKT1 E17
hotspot locus in the RNA sequencing BAM files of BPA1 and BPA3
Fig. 3 CRTC1-MAML2 fusion gene identified in a breast mucoepidermoid carcinoma. a Schematic representation of the CRTC1-MAML2
fusion transcript detected in the breast mucoepidermoid carcinoma BMEC2 by RNA sequencing, depicting the exons and protein domains
involved (top). Vertical lines show the breakpoints of CRTC1 and MAML2. The spanning reads found to cross the genomic breakpoint of the
CRTC1-MAML2 chimeric transcript are shown aligned to the predicted junction sequence (bottom). b Representative Sanger sequencing
electropherogram of cDNA validating the CRTC1-MAML2 fusion junction in BMEC2. c Schematic representation showing the reads per kilobase
per million (RPKM) mapped read counts of each MAML2 exon. The MAML2 fusion breakpoint is represented as a red dashed line.
d Representative photomicrographs of a hematoxylin and eosin-stained section (left) and fluorescence in situ hybridization using three-color
break-apart probes (green, CRTC1; 5′ MAML2, red; 3′ MAML2, orange; right) of BMEC2. Scale bar, 20 μm (d). AcD acidic domain, BD basic domain,
CBD CREB-binding domain, NES nuclear export signal, NLS nuclear localization signal, SD splicing domain, TAD transactivation domain.
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using the Integrative Genomics Viewer (IGV)29, no hotspot
mutations affecting these genes were identified.
CRTC1-MAML2 fusion gene in a breast mucoepidermoid carcinoma
RNA sequencing analysis of BMEC2, a MEC arising in the breast,
revealed the presence of a CRTC1-MAML2 fusion gene (Figs. 1g
and 3a), the hallmark genetic alteration of MECs arising in other
anatomic origins6–8. These findings are in agreement with the
study by Bean et al.30, who reported on two breast MECs
harboring the CRTC1-MAML2 fusion gene. The fusion gene
identified in BMEC2 was predicted to result in a chimeric transcript
encompassing exon 1 of CRTC1 and exons 2–5 of MAML2 (Fig. 3a,
b), akin to MECs in other anatomic locations and to the two breast
MECs previously reported6–8. As predicted, the CRTC1-MAML2
fusion resulted in increased expression of exons 2–5 and
decreased expression of exon 1 of MAML2 (Fig. 3c), and its
presence was confirmed by RT-PCR and FISH using a three-color
break-apart probe (Fig. 3b, d).
DISCUSSION
Given that various salivary gland-like tumors arising in the breast
have been shown to harbor the same genetic alterations as their
salivary gland counterparts10, we posited that breast PAs and
MECs might be underpinned by the oncogenic fusion genes
described in PAs and MECs arising in the salivary glands. Our
analyses resulted in the identification of an HMGA2-WIF1 and a
CTNNB1-PLAG1 fusion gene in breast PAs, and of a CRTC1-MAML2
fusion gene in a breast MEC. The HMGA2 and PLAG1 rearrange-
ments, and the CRTC1-MAML2 fusion genes identified in the breast
PAs and breast MECs of this study, have been reported in PAs and
MECs arising in the salivary gland and in other anatomic
locations6–8,20,21,23,24. Moreover, our findings on breast MECs are
in agreement with the study by Bean et al.30, who reported on the
presence of the CRTC1-MAML2 fusion gene in two breast MECs.
HMGA2 is an oncogene with diverse oncogenic mechanisms, as
it has been shown to induce the activity of E2F1 and AP1, result in
inactivation of p53-dependent apoptosis, and in the activation of
the TGF-β signaling pathway22,31. WIF1 is a tumor suppressor that
encodes for a secreted antagonist that binds Wnt proteins
hampering ligand–receptor interactions32,33. The HMGA2-WIF1
fusion gene identified in BPA3 results in the loss of the 3′ UTR
regulatory sites of HMGA2, resulting in its overexpression and in
increased signaling via TGF-β22,34. It is also predicted to result in
the loss of the WIF domain of WIF1, required for its tumor
suppressor activities, with ensuing Wnt signaling activation32,33.
We have recently reported the presence of an HMGA2-WIF1 fusion
gene in an estrogen receptor-positive breast adenomyoepithe-
lioma (AME) lacking HRAS mutations26. Although the HMGA2 and
WIF1 genomic breakpoints in the HMGA2-WIF1 fusion gene
identified in the HRAS-wild type AME were different than those
identified in BPA3, they resulted in the loss of the 3′UTR of HMGA2
and of the WIF domain of WIF1 (ref. 26), akin to the fusion gene
present in BPA3 reported here. Notably, the previously reported
AME harboring the HMGA2-WIF1 fusion gene26, despite having the
cardinal diagnostic features of AMEs, displayed focal myxochon-
droid stroma, akin to that found in PAs26. We identified a CTNNB1-
PLAG1 fusion gene in BPA2, described in PAs of the salivary gland.
This fusion gene results in promoter swapping between PLAG1
and CTNNB1, leading to increased PLAG1 expression and reduction
of CTNNB1 expression35. Taken together, these findings suggest
that the spectrum of histologic features of breast PAs and AMEs
overlaps, despite the differences in their repertoire of somatic
genetic alterations (i.e. HMGA2 and PLAG1 fusion genes in the
majority of PAs, in contrast with mutations affecting HRAS, PIK3CA,
AKT1, and PIK3R1 in breast AMEs)3,4,28.
MECs of the salivary glands and two breast MECs previously
reported are characterized by the t(11:19) (q21;p13) translocation,
which results in the CRTC1-MAML2 fusion gene6,30. CRTC1 encodes
for the CREB-regulated transcriptional coactivator 1 (ref. 36) and
MAML2 for the NOTCH/RBPJ mastermind-like 2. MAML2 forms
DNA-binding complexes with Rbp-j and NotchIC and augments
Notch signaling37. The CRTC1-MAML2 fusion gene identified in
BMEC2 has been shown to result in activation of the Notch
signaling pathway, be tumorigenic in vitro, and silencing of its
fusion product reportedly inhibits tumor growth38.
Given their rarity, the differential diagnosis of PAs and MECs
arising in the breast from other breast tumors, such as metaplastic
carcinomas and squamous cell carcinomas, respectively, might be
challenging1. The absence of peripheral myoepithelial cell layer
between the epithelium and stroma in PAs together with their
infiltrative appearances, at least focally, makes their distinction
from metaplastic carcinoma of the matrix producing type
challenging, particularly in core biopsies. Such distinction may
have significant management implications. Similarly, the distinc-
tion between MECs and the more aggressive metaplastic
squamous cell carcinoma or the benign papilloma with squamous
metaplasia can be difficult and an additional genomic testing may
help in their accurate diagnosis. Reanalysis of the RNA sequencing
results by Piscuoglio et al.39 and Weigelt et al.40 revealed that
none of the metaplastic breast cancers analyzed in those studies
harbored any of the fusion genes identified in breast PAs and
MECs (data not shown). Our findings suggest that the assessment
of rearrangements involving PLAG1 or HMGA2 in breast PAs, and
of MAML2 rearrangements in breast MECs, might be used as
ancillary tools to aid in the diagnosis of these rare breast tumors.
Our study has important limitations, including the small sample
size due to the rarity of PAs and MECs arising in the breast. In
addition, we could only perform transcriptomic analyses of the
samples included here due to limited available material. Finally, no
fusion genes were identified in one of the breast PAs analyzed,
and its driver has yet to be identified. Despite these limitations,
our findings support the notion that PAs and MECs arising in the
breast harbor genetic alterations akin to those described in their
salivary gland counterparts, and constitute additional examples of
genotypic–phenotypic correlations in breast tumors. These find-
ings may also constitute the basis for the development of ancillary
methods for the diagnosis of these tumors in the breast.
METHODS
Ethics
This study was approved by the Memorial Sloan Kettering Cancer Center
Institutional Review Board (IRB) and local research ethics committees of the
authors’ institutions. Patient consent was obtained if required by
the approved IRB protocols. Formalin-fixed paraffin-embedded (FFPE)
tissue blocks of three breast PAs and one breast MEC were retrieved from
the pathology archives of the authors’ institutions. All samples were
anonymized before analysis.
Cases and RNA extraction
All tumors included in this study were centrally reviewed by four
pathologists (F.P., M.V., F.C.G., J.S.R.-F.) for diagnosis confirmation, following
the diagnostic criteria put forward by the World Health Organization
(WHO)41. The three breast PAs and one breast MEC were microdissected
from eight-micron-thick histologic sections under a stereomicroscope
(Olympus SZ61) to ensure a tumor cell content >80%, and RNA was
extracted using the RNeasy FFPE Kit.
RNA sequencing and identification of fusion genes
FFPE-derived RNA from two breast PA and one breast MEC were subjected
to paired-end RNA sequencing following the standard protocols used at
the Integrated Genomics Operation at MSKCC42, as previously
described19,26,43. INTEGRATE44, deFuse45, and FusionCatcher46 were used
F. Pareja et al.
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to identify read pairs supporting chimeric transcripts, followed by
exclusion of candidate fusion transcripts and read-through candidates
identified in a set of 297 normal breast tissues from the TCGA47. The
Bayesian probability to constitute drivers of the remaining candidate
fusion genes supported by at least two spanning reads was assessed using
OncoFuse (v1.0.9b2)48. Reads per kilobase million (RPKM) values were
calculated from raw counts after normalization for sequencing depth and
following adjustment for length of genes. Data are available as described
on the Data availability statement49,50.
ARCHER FusionPlex
One breast PA with insufficient material for RNA sequencing was subjected
to Archer FusionPlex assay, an RNA-based panel that uses Archer Anchored
Multiplex PCT technology and next-generation sequencing for the
identification of fusion genes51 at the Integrated Genomics Operation at
MSKCC, as previously described52. Archer FusionPlex data were analyzed
using Archer Software (v4.0.10).
RT-PCR for fusion gene validation
RNA was reverse-transcribed using SuperScript VILO Master Mix (Thermo-
Fisher Scientific), following the manufacturers’ instructions. PCR amplifica-
tion of 10 ng cDNA was conducted using fusion gene-specific primers sets
designed based on the identified breakpoints (Supplementary Table 3).
PCR fragments were purified with ExoSAP-IT (ThermoFisher Scientific) and
subjected to Sanger Sequencing. Sequence electropherograms of the
forward and reversed strands were manually inspected.
Fluorescence in situ hybridization
Cases in this study with available material were subjected to FISH analysis
for rearrangements involving HMGA2 and PLAG1 or for the presence of the
CRTC1-MAML2 fusion gene following validated protocols at the Molecular
Cytogenetics Core of MSKCC, as previously described19. HMGA2 and PLAG1
rearrangements were assessed using dual-color break-apart probes
consisting of bacterial artificial chromosome (BAC) clones mapping to 5′
HMGA2 (RP11-230G5, RP11-662G15, red) and 3′ HMGA2 (RP11-937C6, RP11-
167E10, green) and to 5′ PLAG1 (RP11-92A9, RP11-111I18, red) and 3′
PLAG1 (RP11-144E19, RP11-246A9, green), respectively. The presence of
CRTC1-MAML2 fusion gene was assessed using a three-color break-apart
probe consisting of BAC clones mapping to CRTC1 (RP11-282P1, RP11-
908B10, green), 5′MAML2 (RP11-385G6, RP11-8N17, orange), and 3′MAML2
(RP11-277H22, RP11-111I14, orange). FISH analysis was conducted by
observers blinded to the results of the RNA sequencing and ARCHER
FusionPlex analyses. Cases were considered positive if the rearrangement
was identified in >15% tumor cells.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The data generated and analyzed during this study are described in the following
data record: https://doi.org/10.6084/m9.figshare.12199781 (ref. 49). The RNA sequen-
cing data have been deposited in the NCBI Sequence Read Archive under the project
accession number SRP257886 (https://identifiers.org/ncbi/insdc.sra:SRP257886)50.
The histologic images, fluorescence in situ hybridization, and Sanger sequencing
data will be provided upon reasonable request to Dr. Fresia Pareja. The Archer
FusionPlex data will be provided upon reasonable request to Dr. Arnaud Da
Cruz Paula.
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